- Merck & Co.
Merck & Co., Inc.
(Merck Sharp & Dohme (MSD) outside the United States and Canada)
Type Public Traded as NYSE: MRK
Dow Jones Industrial Average Component
Industry Pharmaceuticals Founded 1891 as a subsidiary of Merck KGaA
1917 as an independent company
Headquarters Whitehouse Station, New Jersey, United States Key people Richard T. Clark
(President and CEO)
Products See more complete products listing. Revenue US$ 45.987 billion (2010) Operating income US$ 1.653 billion (2010) Net income US$ 861 million (2010) Total assets US$ 105.781 billion (2010) Total equity US$ 56.805 billion (2010) Employees 94,000 (2010) Website Merck.com
Merck & Co., Inc. (NYSE: MRK), also known as Merck Sharp & Dohme or MSD outside the United States and Canada, is one of the largest pharmaceutical companies in the world. The Merck headquarters is located in Whitehouse Station, New Jersey, an unincorporated area in Readington Township. The company was established in 1891 as the United States subsidiary of the German company now known as Merck KGaA. In common with many other German assets in the United States, Merck & Co. was confiscated in 1917 during World War I and then set up as an independent company. Currently, it is one of the seven largest pharmaceutical companies in the world both by market capitalization and revenue.
Merck & Co. or MSD describes itself as a "a global research-driven pharmaceutical company. Merck discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health, directly and through its joint ventures." The Merck Company Foundation has distributed over $480 million to educational and non-profit organizations since it was founded in 1957.
Merck publishes The Merck Manuals, a series of medical reference books. These include the Merck Manual of Diagnosis and Therapy, the world's best-selling medical textbook, and the Merck Index, a collection of information about chemical compounds.
- 1 History
- 2 Corporate governance
- 3 Products
- 4 Patient assistance programs
- 5 Vioxx
- 6 Cordaptive
- 7 Phony medical journal
- 8 Medicaid overbilling
- 9 Environmental record
- 10 Isentress
- 11 Singulair
- 12 See also
- 13 References
- 14 External links
Merck & Co. traces its origins to Friedrich Jacob Merck who purchased a drug store in Darmstadt, Germany in 1668 and also to Emanuel Merck, who took over the store several generations later, in 1816. Emanuel and his successors gradually built up a chemical-pharmaceutical factory that produced—in addition to raw materials for pharmaceutical preparations—a multitude of other chemicals.
In 1891, George Merck established his roots in the United States and set up Merck & Co. in NY as the US arm of the family partnership, E. Merck (named for Emanuel Merck), which is now Merck KGaA. Merck & Co. was confiscated in 1917 during World War I and set up as an independent company in the United States. Between the wars and during World War II, the company was led by George W. Merck, who oversaw America's germ-warfare research at Fort Detrick. Today, the US company has about 51,000 (S&P NetAdvantage) employees in 120 countries and 31 factories worldwide. It is one of the top 7 pharmaceutical companies worldwide, larger than its German ancestor, which currently employs around 41,000 people in 67 countries.
In 1965 Merck acquired Charles E. Frosst Ltd. of Montreal (founded 1899) and created Merck-Frosst Canada Inc. as its Canadian subsidiary and pharmaceutical research facility. (In July 2010, Merck announced that this would be one of several operations to be closed.) The company was renamed Merck Canada in 2011.
In 2005, CEO Raymond Gilmartin retired at the age of 64 following Merck's voluntary worldwide withdrawal of Vioxx. Former president of manufacturing Richard Clark was named CEO and President of the company. In December 2010 Kenneth Frazier was announced CEO with Richard Clark Retiring in October 2011.
On December 10, 2007, the company's share price reached a five-year high of $60.77. However, the share price of Merck since trended down, reaching an intraday low of $20.05 per share on March 9, 2009.
In November 2009, Merck announced that it would merge with competitor Schering-Plough in a US$41 billion deal. The purchase was a "reverse merger" in which Schering-Plough would be renamed Merck and continue as the surviving public corporation. The new company would be operated under the trade name Merck in the United States and Canada and elsewhere under the trade name MSD.
On May 4, 2010, Merck announced its 2010 first quarter financial results. The company reported, among other things, that its financial results were affected both by the merger with Schering-Plough and tax charges related to the recently enacted health reform legislation. During the early months of 2010, Merck's stock began a slow slide downward. The stock peaked at 41.03 on January 20, 2010. By April 22, 2010, the stock had fallen to 33.77, a loss of 17.7%. This loss of stock is almost equal to the loss of 17.6% the American pharmaceutical company Pfizer had during this same time period. The slide is most likely caused by the declining productivity and increasing cost of pharmaceutical development.
July 2011: Inline with an effort to save as much as $4.6 billion per year, Merck & Co. plans to cut an additional 12,000 to 13,000 employees or 14 percent of current Merck's total workforce of 91,000 employees by the year 2015.
As of February 25, 2011[update] the members of the board of directors of Merck & Co. are: Richard T. Clark, Leslie A. Brun, Thomas R. Cech, Ph.D., Kenneth C. Frazier, Thomas H. Glocer, Steven F. Goldstone, William B. Harrison, Jr., Harry R. Jacobson, M.D., William N. Kelley, M.D., C. Robert Kidder, Rochelle B. Lazarus, Carlos E. Represas, Patricia F. Russo, Thomas E. Shenk, Ph.D., Anne M. Tatlock, Craig B. Thompson, M.D., Wendell P. Weeks, and Peter C. Wendell.
Products on the market
- Antivenin – for the treatment of black widow spider (Latrodectus mactans) bites
- Arcoxia (etoricoxib) – for the symptomatic treatment of osteoarthritis (not approved in the US, but approved and sold in Europe, Latin America, the Asia-Pacific region and Middle East/Northern Africa)
- Cancidas (caspofungin) – an echinocandins antifungal drug for treatment of Aspergillus and Candida.
- Cosopt (dorzolamide and timolol) – reduces intraocular pressure in people with glaucoma or ocular hypertension.
- Cozaar (losartan) – used to treat hypertension, to reduce the risk of strokes and to treat diabetic nephropathy.
- Crixivan (indinavir) – a protease inhibitor HIV medication.
- Emend (aprepitant) – treats vomiting and nausea brought about by chemotherapy.
- Emend Injection (fosaprepitant dimeglumine) – an intravenous drug for nausea and vomiting caused by chemotherapy
- Emflex (acemetacin) – a non-steroidal anti-inflammatory drug.
- Fosamax (alendronate) – osteoporosis medication.
- Fosamax Plus D (alendronate/vitamin D) – osteoporosis medication.
- Gardasil (HPV vaccine) – a vaccine against human papillomavirus, a sexually transmitted disease.
- Hyzaar (losartan/hydrochlorothiazide) – used to treat hypertension, to reduce the risk of strokes and to treat diabetic nephropathy.
- Isentress (raltegravir) – HIV integrase inhibitor.
- Janumet (sitagliptin/metformin) – an oral anti-diabetic drug for the treatment of type 2 diabetes.
- Januvia (sitagliptin) – a dipeptidyl peptidase-4 inhibitor for the treatment of diabetes
- Maxalt (rizatriptan) – one of many triptans used to treat migraines.
- M-M-R II (MMR Vaccine) – immunization against measles, mumps and rubella.
- Pneumovax 23 (Pneumococcal polysaccharide vaccine) – a vaccine used to prevent Streptococcus pneumoniae infections such as pneumonia and septicaemia.
- Primaxin (imipenem with cilastatin) – a broad spectrum carbapenem antibiotic.
- Prinzide (lisinopril/hydrochlorothiazide) – anti-hypertensive combination of an ACE inhibitor and a diuretic.
- Propecia/Proscar (finasteride) – used for alopecia (male pattern baldness) and prostatic conditions.
- ProQuad (MMRV vaccine) – a vaccine for simultaneous vaccination against measles, mumps, rubella, and varicella in children.
- Recombivax HB (hepatitis B vaccine) – a vaccine that protects against hepatitis B.
- Rotateq – a vaccine to prevent rotavirus gastroenteritis, a leading cause of severe diarrhea in infants and young children ages 0 to 12.
- Singulair (montelukast) – an asthma medication that blocks leukotrienes.
- Timoptic (timolol) – a non-selective beta-adrenergic receptor blocker used to treat high blood pressure and prevent heart attacks.
- Tredaptive (laropiprant/ER niacin) – a new lipid-modifying therapy for patients with dyslipidemia and primary hypercholesterolemia (not approved in the US, but approved in the European Union)
- Trusopt (dorzolamide) – reduces intraocular pressure in people with glaucoma or ocular hypertension.
- Vaqta (hepatitis A vaccine) – a vaccine that protects against hepatitis A.
- Varivax (Varicella vaccine) – a vaccine that protects against chickenpox.
- Vytorin (ezetimibe/simvastatin) – a combination cholesterol-lowering preparation marketed in collaboration with Schering-Plough.
- Zetia (ezetimibe) – cholesterol absorption inhibitor which lowers LDL co marketed by Schering-Plough
- Zocor (simvastatin) – a cholesterol-lowering statin.
- Zolinza (vorinostat) – a histone deacetylase inhibitor for the treatment of cutaneous T cell lymphoma.
- Zostavax – a vaccine for prevention of shingles in adults older than 50 years of age.
Products from Schering-Plough
- Intron A
- Temodar, Temodal, Temozolomide
- Home Again Pet Recovery System
- Dr. Scholl's
- A+D Original Ointment
- A+D Zinc Oxide Cream
- Bain de Soleil
Products under development
- An antidote for statin toxicity involving CoQ10 (which has been held for over 20 years without producing it)
Patient assistance programs
In the early 1950s, Merck & Co. was one of the first pharmaceutical companies to provide patient assistance programs in the U.S. to those unable to afford their medications. Currently, Merck & Co. offers 7 patient assistance programs, each with specific eligibility requirements.
- Act Program For Emend
- Emend (aprepitant)
- ACT Program For Zolinza
- Zolinza (vorinostat)
- Merck Anti-Infective Hotline
- Merck Patient Assistance Program
- Merck Prescription Discount Program
- Merck Vaccine Patient Assistance Program
- SUPPORT Program For Crixivan
- Crixivan (indinavir)
In 1999, the U.S. Food and Drug Administration (FDA) approved Vioxx (known generically as rofecoxib), a Merck product for treating arthritis. Vioxx was stronger than existing medications, while easier on the stomach than established anti-inflammatory drugs such as naproxen. Vioxx became one of the most prescribed drugs in history. According to internal e-mail traffic released at a later lawsuit, Merck had a list of doctors critical of Vioxx to be "neutralised" or "discredited." "We may need to seek them out and destroy them where they live," wrote an employee. Also alleged were intimidation of researchers and impingement upon academic freedom.
Thereafter, studies by Merck and by others found an increased risk of heart attack associated with Vioxx use when compared with naproxen. There was no indication of this risk in the original placebo-controlled safety trials, and it was possible that the effect was more related to naproxen decreasing the risk of heart attacks than one of Vioxx increasing the risk. Merck adjusted the labeling of Vioxx to reflect possible cardiovascular risks in 2002.
On September 23, 2004, Merck received information about results from a clinical trial it was conducting that included findings of increased risk of heart attacks among Vioxx users who had been using the medication for over eighteen months. On September 28, 2004, Merck notified the FDA that it was voluntarily withdrawing Vioxx from the market, and it publicly announced the withdrawal on September 30. The FDA has since recommended that Vioxx be put back on the market, but with a more prominent warning regarding cardiovascular risks on its label.
On November 5, 2004 the medical journal The Lancet published the results of its analysis of the available studies. It concluded that "the unacceptable cardiovascular risks of Vioxx (rofecoxib) were evident as early as 2000..." The journal's editors criticized Merck for having kept the drug on the market as long as it did before withdrawing it, and also criticized the FDA for its failure of regulatory oversight.
About 50,000 people have sued Merck claiming that they or their family members have suffered medical problems such as heart attacks or strokes after taking Vioxx. In 2005, Merck was found liable in the first case that went to trial and the plaintiff was awarded $253.4 million in damages; however, the judgement was subsequently reduced to $20 million and then, upon appeal, the verdict was reversed in 2008. In November 2007, Merck proposed to pay $4.85 billion to settle most of the pending Vioxx lawsuits. The settlement will require that claimants provide medical proof of having suffered a heart attack or a stroke and show they received at least 30 Vioxx pills. This proposed settlement is generally viewed by industry analysts and investors as a victory for Merck, considering that original estimates of Merck's liability reached as high as $50 billion. As of mid-2008, plaintiffs have prevailed in only three of the twenty cases that have reached juries, all with relatively small awards.
On May 20, 2008, Merck was found liable for using deceptive marketing tactics to promote Vioxx and 30 states will split the $58 million settlement. The amount is the largest multi-state settlement against a pharmaceutical company. All its new television pain-advertisements must be vetted by the Food and Drug Administration and changed or delayed upon request until 2018.
On September 4, 2007, Merck & Co. introduced the experimental drug Cordaptive, which can both raise HDL and lower LDL (combining an extended-release form of the B vitamin niacin with laropiprant, a novel compound intended to inhibit flushing or redness of the face). Cordaptive caused 18% drop in levels of LDL-C00, a 26% drop in triglycerides, and a 20% increase in HDL-C. Merck's cholesterol statin drug Zocor has seen sales plunge since its patent expired in 2006. In addition, Merck and partner Schering-Plough Corp. jointly market two other cholesterol drugs, Zetia and Vytorin.
On April 24, 2008, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of the combination, to be marketed in Europe as Tredaptive.
Phony medical journal
From 2002 through 2005 the Australian affiliate of Merck sponsored the eight issues of a medical journal, the Australasian Journal of Bone and Joint Medicine, published by Elsevier. Although it gave the appearance of being an independent peer-reviewed journal, without any indication that Merck had paid for it, the journal actually reprinted articles that originally appeared in other publications and that were favorable to Merck. The misleading publication came to light in 2009 during a personal injury lawsuit filed over Vioxx; 9 of 29 articles in the journal's second issue referred positively to Vioxx. In 2009, the CEO of Elsevier's Health Sciences Division, Michael Hansen, admitted that the practice was "unacceptable".
A US Justice Department fraud investigation began in 2000 when allegations were brought in two separate lawsuits filed by whistleblowers under the False Claims Act. They alleged that Merck failed to pay proper rebates to Medicaid and other health care programs and paid illegal remuneration to health care providers. On February 7, 2008 Merck agreed to pay more than $650 million to settle charges that it routinely overbilled Medicaid for its most popular medicines. The federal government received more than $360 million, and 49 states and Washington, DC, over $290 million. One whistleblower received a $68 million reward. Merck made the settlement without an admission of liability or wrongdoing.
Merck & Co. used methylene chloride which is an animal carcinogen and is on the United States Environmental Protection Agency's list of pollutants. To get rid of this problem Merck chemists and engineers discovered a new way to manufacture products without using methylene chloride. The new way of creating chemicals seemed to have fewer negative environmental effects. Merck has also changed its equipment to protect the environment. Merck installed a computerized distributed control system that runs chemical reaction steps more effectively and has increased the process of operations by 50 percent. With the new machines, they have eliminated the need for the disposal and storage of harmful waste. The biological oxygen demand was reduced by 75% with a new process to help with water waste and other polluting waste. In 1991, Kelco, owned by Merck, was responsible for 1/3 of the volatile organic compound (VOC) emission pollution in the San Diego area. The ground level ozone was causing health problems such as lung tissue damage and making the lungs easily vulnerable to harmful bacteria. In 1996 Merck paid 1.8 million dollars in a settlement that accused them of polluting the air. In addition, new machines were installed to cut the air pollution that the company's facilities were giving off. The new machines reduce the smog level emissions by 680,000 lb (310,000 kg) a year.
Raltegravir (Isentress), Merck's HIV integrase inhibitor was unanimously recommended for accelerated approval by the FDA's Advisory Committee on September 5, 2007. Isentress works by acting on a specific enzyme in HIV, integrase, that allows the RNA from HIV to become part of human DNA in the replication process. Isentress was approved by the FDA on October 12, 2007.
The FDA is looking into a link between the Merck drug Singulair, suicide and other psychological side effects, and is conducting research to see if Singulair should be reviewed further. Singulair works on blocking the Leukotriene pathway in both Asthma and Allergic Rhinitis.
- ^ a b c d e f "2010 Form 10-K, Merck & Co., Inc.". United States Securities and Exchange Commission. http://www.sec.gov/Archives/edgar/data/310158/000095012311019286/y87773e10vk.htm.
- ^ Princeton University and The Merck Company Foundation Announce Creation Of New Global Health Scholars Program and Lecture Series
- ^ "Montreal plant among 17 closed by drugmaker Merck". The Star (Toronto). July 8, 2010. http://www.thestar.com/business/article/833712--montreal-plant-among-17-closed-by-drugmaker-merck.
- ^ Singer, Natasha (March 10, 2009). "Merck to Buy Schering-Plough for $41.1 Billion". The New York Times. http://www.nytimes.com/2009/03/10/business/10drug.html. Retrieved 2009-11-14.
- ^ "Merck and Schering-Plough to Complete Merger Today" (Press release). Merck & Co.. November 3, 2009. http://www.merck.com/newsroom/news-release-archive/corporate/2009_1103.html. Retrieved 2009-11-13.
- ^ "New Merck Begins Operations" (Press release). Merck & Co.. November 4, 2009. http://www.merck.com/newsroom/news-release-archive/corporate/2009_1104.html. Retrieved 2009-11-13.
- ^ "Notice of Reorganization Event". November 12, 2009. http:///phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MjA0NDh8Q2hpbGRJRD0tMXxUeXBlPTM=&t=1. Retrieved 2009-11-13.
- ^ http://thestockmarketwatch.com/stock-market-news/recent-events/health/merck-plans-13k-job-cuts/11068
- ^ "Board of Directors". http://www.merck.com/about/leadership/board-of-directors/home.html. Retrieved 2011-02-25.
- ^ Freepatentsonline.com, Merck's patent for "a pharmaceutical composition and method of counteracting HMG-CoA reductase inhibitor-associated elevated transaminase levels"
- ^ "Merck to Create New Patient Assistance Program for Vaccines" Retrieved on May 20, 2008.
- ^ "Patient Assistance - Available Prescription Assistance Programs From Merck & Co." Retrieved on May 20, 2008.
- ^ Merck Patient Assistance Programs
- ^ Rout, Milanda (2009-04-01). "Vioxx maker Merck and Co drew up doctor hit list". The Australian. http://www.theaustralian.news.com.au/story/0,25197,25272600-2702,00.html. Retrieved 2009-04-26. [dead link]
- ^ Finance.senate.gov
- ^ Elsevier
- ^ a b c Courts Reject Two Major Vioxx Verdicts, The New York Times, May 30, 2008
- ^ Merck proposes $4.85B Vioxx settlement, USA Today, November 12, 2007
- ^ "Merck's outlook revised to developing from negative on Vioxx agreement - Moody's". forbes.com. Thomson Financial. 2007-11-12. http://www.forbes.com/feeds/afx/2007/11/12/afx4326773.html. Retrieved 2009-05-04.
- ^ Arizona gets $2.3 Million from Vioxx Settlement 92.3 KTAR Retrieved on May 19, 2008
- ^ Merck Agrees to Settlement Over Vioxx Ads, The New York Times, May 20, 2008]
- ^ Yahoo.com, Merck niacin drug controls cholesterol
- ^ Merck & Co., Inc. press release - Two Merck Medicines Recommended for Approval in the European Union Retrieved on April 30, 2008.
- ^ Merck & Co., Inc. press release - Merck Receives Not Approvable Letter from FDA for MK-0524A (ER niacin/laropiprant) Retrieved on April 30, 2008.
- ^ Carey, John (April 29, 2008). "FDA Rejects Merck's Cordaptive". BusinessWeek. http://www.businessweek.com/bwdaily/dnflash/content/apr2008/db20080429_182260.htm. Retrieved 2009-11-13.
- ^ Merck & Co., Inc. press release - TREDAPTIVE (nicotinic acid /laropiprant) Approved in the European Union: New Lipid-Modifying Therapy to Treat LDL-C, HDL-C and Triglycerides Retrieved on July 26, 2008.
- ^ "Tredaptive European Public Assessment Report". European Medicines Agency. http://www.emea.europa.eu/humandocs/Humans/EPAR/tredaptive/tredaptive.htm. Retrieved November 13, 2009.
- ^ Singer N (2009-05-13). "Merck paid for medical 'journal' without disclosure". The New York Times. http://www.nytimes.com/2009/05/14/business/14vioxxside.html. Retrieved 2009-06-17.
- ^ "Statement From Michael Hansen, CEO Of Elsevier's Health Sciences Division, Regarding Australia Based Sponsored Journal Practices Between 2000 And 2005" (Press release). Elsevier. May 7, 2009. http://www.elsevier.com/wps/find/authored_newsitem.cws_home/companynews05_01203. Retrieved Nov 20, 2009. "It has recently come to my attention that from 2000 to 2005, our Australia office published a series of sponsored article compilation publications, on behalf of pharmaceutical clients, that were made to look like journals and lacked the proper disclosures. This was an unacceptable practice, and we regret that it took place."
- ^ a b Johnson, Carrie (February 8, 2008). "Merck to Pay $650 Million In Medicaid Settlement". The Washington Post. http://www.washingtonpost.com/wp-dyn/content/article/2008/02/07/AR2008020701336.html. Retrieved 8 February 2010.
- ^ USDOJ.GOV, Merck to Pay More than $650 Million to Resolve Claims of Fraudulent Price Reporting and Kickbacks. February 7, 2008
- ^ Pharmalot.com: Ed Silverman, Merck To Pay $670 Million Over Medicaid Fraud.
- ^ "Merck Resolves Federal and State Investigations Related to Certain Past Pricing And Certain Past Sales and Marketing Activities". Merck. February 7, 2008. http://www.merck.com/newsroom/news-release-archive/corporate/2008_0207.html. Retrieved 8 February 2010. [dead link]
- ^ P2pays.org
- ^ ET 10/96: Repairing a legacy of pollution by Kelco
- ^ U.S. settles $1.8 million pollution case with Merck and Monsanto | Newsroom | US EPA
- ^ Merck.com FDA Advisory Committee Unanimously Recommends Accelerated Approval of ISENTRESS (raltegravir), Merck's Investigational Oral Integrase Inhibitor, for Treatment of HIV
- ^ "FDA approval of Isentress (raltegravir)". U.S. Food and Drug Administration (FDA). June 25, 2009. http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm124040.htm. Retrieved 2009-11-15.
- ^ "FDA looks into Singulair, risks of suicidal thoughts", USA Today
- About Merck & Co.
- The Merck Manuals
- Yahoo! - Merck & Co., Inc. Company Profile
- About Merck KGaA
- History of Merck
- Information about first lawsuit against Merck from Yahoo! Finance
- NEJM -Failing the Public Health — Rofecoxib, Merck, and the FDA
- Merck Frosst Canada
- Your Health Now
- Merck & Co. Patient Assistance Programs
- Peggy Peck (2008-10-22). "Economic Slowdown Sees Job Cuts at Merck and Drop in Prescription Drug Sales". MedPage Today. http://www.medpagetoday.com/PublicHealthPolicy/PublicHealth/11410. Retrieved 2008-10-22.
Merck & Co., Inc. Corporate directors: Products: Publications: Pharmaceutical companies of the United StatesAbbott Laboratories • Acorda Therapeutics • Aderis Pharmaceuticals • Adolor Corporation • Alcon • Alexion Pharmaceuticals • Alkermes (company) • Allergan • Alza • Amgen • Amylin Pharmaceuticals • ARIAD Pharmaceuticals • ARYx Therapeutics, Inc. • Avax Technologies • AVI BioPharma • Barr Pharmaceuticals • Baxter International • BioCryst Pharmaceuticals • Biogen Idec • Biolex • Biovest • Biovista • Bradley Pharmaceuticals • Bristol-Myers Squibb • CancerVax • Centocor Ortho Biotech, Inc. • Century Pharmaceuticals • Cephalon • Ceragenix Pharmaceuticals • Combe Incorporated • Cortex Pharmaceuticals • CoTherix • Covance • Covidien • Cutter Laboratories • CytoSport • CytRx • Danco Laboratories • DNAPrint Genomics • EPIX Pharmaceuticals Inc • Eli Lilly and Company • Elorac • Endo Pharmaceuticals • Ethicon Endo-Surgery • Ethicon Inc. • Forest Laboratories • GenVec • Genentech • Genta (company) • Gilead Sciences • Hospira • ImClone Systems • Institute for OneWorld Health • ISTA Pharmaceuticals • Ivax Corporation • Johnson & Johnson • Kinetic Concepts • King Pharmaceuticals • Kinray • KV Pharmaceutical • Leiner Health Products • Mallinckrodt Incorporated • Martek Biosciences Corporation • S. E. Massengill Company • McKesson Corporation • McNeil Laboratories • Melior Discovery • Mentholatum • Merck & Co. • Miles Laboratories • Mylan Inc. • Myriad Genetics • Nereus Pharmaceuticals • Northwest Biotherapeutics • Norwich Pharmaceuticals • Nuvelo • Organon International • Ortho Pharmaceutical • Ortho-McNeil Pharmaceutical • OSI Pharmaceuticals • Ovation Pharmaceuticals • Panacos Pharmaceuticals • Par Pharmaceutical • Parke-Davis • Perrigo • Pfizer • Pharmaceutical Product Development • Prasco Laboratories • Procter & Gamble • Proteon Therapeutics • Purdue Pharma • Qualitest • Quark Pharmaceuticals • Regeneron • Repros Therapeutics • Respa Pharmaceuticals • Rib-X Pharmaceuticals • Savage Laboratories • Schering-Plough • G. D. Searle & Company • Smith, Kline & French • Spectrum Pharmaceuticals • Sterling Drug • Tanox • TAP Pharmaceutical Products • Tec Laboratories • Teva Pharmaceutical Industries • Tiens Biotech Group • Titan Pharmaceuticals • Trevena Inc • Trubion • Upjohn • Upsher-Smith Laboratories • Valeant Pharmaceuticals International • Ventria Bioscience • Verus Pharmaceuticals • Vion Pharmaceuticals, Inc. • ViroPharma • Vital Pharmaceuticals • Watson Pharmaceuticals • West Pharmaceutical Services • Wyeth • Zonite Products Corporation List of pharmaceutical companies
Wikimedia Foundation. 2010.